Case Series to Evaluate Patient Specific Implants (PSI) in Polyether Ether Ketone (PEEK) Performance After 2 Years
This study has been withdrawn prior to enrollment.
Sponsor:
Synthes GmbH
Information provided by (Responsible Party):
Synthes GmbH
ClinicalTrials.gov Identifier:
NCT01282645
First received: January 24, 2011
Last updated: March 21, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this retrospective study is to evaluate the percentage of patients with device related adverse events (infection, rejection, dislocation, fracture of the implant) in the first 24 months after implantation.
| Condition | Intervention |
|---|---|
|
E04.525.190 Craniotomy Craniectomy |
Device: PSI in PEEK |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | A Retrospective Case Series to Evaluate the Long Term Outcome of the Use of Synthes Patient Specific Implants (PSI®) Made of Polyether Ether Ketone (PEEK) for the Treatment of Cranial Defects in Patients With a Mature Skeleton |
Further study details as provided by Synthes GmbH:
Primary Outcome Measures:
- Device related adverse events [ Time Frame: 0-24 months post initial implantation ] [ Designated as safety issue: Yes ]
Percentage of patients with the following device related adverse events:
- infection
- rejection
- dislocation
- fracture
Secondary Outcome Measures:
- Explantation [ Time Frame: 0 months - study visit at least 24 months after implantation (or scheduled up to 3 months after the study visit) ] [ Designated as safety issue: No ]Explantation, as a result of a device-related adverse event or for another reason
- Cosmetic result [ Time Frame: surgery - at discharge ] [ Designated as safety issue: No ]Evaluation of the cosmetic result by the surgeon by means of a VAS 0-100, immediately after the surgery or until the patient was discharged from the hospital (any timepoint available)
- Cosmetic result [ Time Frame: at the study visit, which is at least 24 months after implantation ] [ Designated as safety issue: No ]Evaluation of the cosmetic result by the surgeon by means of a VAS 0-100, during the study visit, at least 24 months after implantation (see inclusion criteria)
- Clinical result [ Time Frame: surgery - at discharge ] [ Designated as safety issue: No ]Evaluation of the clinical result by the surgeon by means of a VAS 0-100, immediately after the surgery or until the patient was discharged from the hospital (any timepoint available)
- Clinical result [ Time Frame: At the study visit, which is at least 24 months after implantation ] [ Designated as safety issue: No ]Evaluation of the cosmetic result by the surgeon by means of a VAS 0-100, during the study visit, at least 24 months after implantation (see inclusion criteria)
- Pressure sensitivity [ Time Frame: At the study visit, which is at least 24 months after implantation ] [ Designated as safety issue: No ]Evaluation of the pressure sensitivity by the patient (or next of kin appreciation in case of severe disability) by means of a VAS 0-100, during the study visit, at least 24 months after implantation (see inclusion criteria)
- Heat / cold sensitivity [ Time Frame: At the study visit, which is at least 24 months after implantation ] [ Designated as safety issue: No ]Evaluation of the heat/cold sensitivity by the patient (or next of kin appreciation in case of severe disability) by means of a VAS 0-100, during the study visit, at least 24 months after implantation (see inclusion criteria)
- Cosmetic result [ Time Frame: At the study visit, which is at least 24 months after implantation ] [ Designated as safety issue: No ]Evaluation of the cosmetic result by the patient (or next of kin in case of severe disability) by means of a VAS 0-100, during the study visit, at least 24 months after implantation (see inclusion criteria)
- Event-free survival [ Time Frame: 0 months - at the study visit, which is at least 24 months after implantation ] [ Designated as safety issue: Yes ]
Number of months of event-free survival, in terms of device related adverse events:
- Infection (superficial and/or deep) [Time frame 0 months - study visit]
- Rejection of the implant [Time frame 0 months - study visit]
- Dislocation of the implant [Time frame 0 months - study visit]
- Fracture of the implant [Time frame 0 months - study visit]
| Enrollment: | 0 |
| Study Start Date: | July 2011 |
| Estimated Study Completion Date: | January 2012 |
| Estimated Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
PSI in PEEK
All study subjects have received a Patient Specific Implant (PSI) made of PEEK to repair a cranial defect
|
Device: PSI in PEEK
A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
Other Name: Patient Specific Implant in Polyether Ether Ketone
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
In 30 clinics worldwide, all patients who received a PSI in PEEK at least 2 years ago, who fullfil the in-and exclusion criteria, will be asked to participate
Criteria
Inclusion Criteria:
- Males or females age 18 years or over at the time of inclusion into the study
- Received a Synthes PSI® made of PEEK intended for replacement of bony voids in the cranial/craniofacial skeleton at least 24 months before inclusion in the study
- Ability to obtain written informed consent from the recipient or the recipient's legal guardian
- Ability to comply with the procedures described in the protocol, including responding to simple questionnaires either by the recipient in person or by a next relative (spouse, parent) who lives with the recipient
Exclusion Criteria:
- Patient was contraindicated to receive a PSI made of PEEK at the time of implantation
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01282645
Show 30 Study Locations
Show 30 Study LocationsSponsors and Collaborators
Synthes GmbH
Investigators
| Principal Investigator: | Frédéric Lauwers, MD | Centre Hospitalier Universitaire de Toulouse, Toulouse, France |
More Information
No publications provided
| Responsible Party: | Synthes GmbH |
| ClinicalTrials.gov Identifier: | NCT01282645 History of Changes |
| Other Study ID Numbers: | STU-CMF-C-16-204-01 |
| Study First Received: | January 24, 2011 |
| Last Updated: | March 21, 2013 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé France: Conseil National de l'Ordre des Médecins France: Institutional Ethical Committee |
Keywords provided by Synthes GmbH:
|
Cranial defect PSI patient specific implant PEEK |
polyether ether ketone craniectomy craniotomy |
ClinicalTrials.gov processed this record on June 18, 2013